halometasone has been researched along with Eczema* in 11 studies
9 trial(s) available for halometasone and Eczema
Article | Year |
---|---|
Staphylococcus aureus colonization and chronic hand eczema: a multicenter clinical trial.
Chronic hand eczema is a common chronic inflammatory skin disease that influences public health. Staphylococcus aureus colonization plays important roles in chronic hand eczema morbidity and progression, which also correlated to chronicity and severity of the disease. In this multicenter clinical trial, we aim to investigate the relationship between S. aureus colonization and chronic hand eczema. Eighty patient volunteers diagnosed with chronic hand eczema in 4 hospitals from 4 cities participated in this study. Staphylococcus aureus colonization was determined using Polymerase Chain Reaction and fluorescent labeling probe to rapidly detect the endemic thermostable nuclease gene nuc of S. aureus in clinical samples. All patients were treated with Halometasone Triclosan Cream for 2 weeks. The changes of clinical symptom scores were observed during the follow-up time. We found that the severity of chronic hand eczema was related to S. aureus colonization. Chronic hand eczema would remain severer than others if S. aureus colonization was not eliminated. Eliminating S. aureus colonization could provide good effectiveness in treatment of chronic hand eczema. Therefore, we make a proposal that detection and treatment of S. aureus should be considered in the clinical treatment of chronic hand eczema. Topics: Adult; Aged; Betamethasone; Chronic Disease; Dermatologic Agents; Drug Combinations; Eczema; Female; Hand; Humans; Male; Middle Aged; Prognosis; Severity of Illness Index; Skin Cream; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Triclosan | 2019 |
Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels.
The aim of the study was to investigate the efficacy and safety of halometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol (COR) levels. Sixty consecutive outpatients diagnosed with chronic generalized eczema between January and April 2017 were included and divided into groups A, B, and C with a lesion area of 30%-40%, 41%-50%, and 51%-60%, respectively. Groups A, B, and C were treated with halometasone cream with a daily dose of 15 g, 20 g, and 30 g for 7-14 days, respectively. Ten patients were randomly selected from each group for serum COR measurement at days 0, 7, and 14. On day 14, group B had significantly higher cure rate (47.1%) than groups A (17.9%) and C (13.3%) and significantly higher effectiveness rate (82.4%) than group C (40.0%) (all Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Eczema; Female; Humans; Hydrocortisone; Male; Middle Aged; Prospective Studies; Skin Cream; Young Adult | 2017 |
An overview of international clinical trials with halometasone cream.
In international multicentre comparative clinical trials carried out by dermatologists in 717 patients with non-infected acute eczematous dermatoses at 28 trial centres in Austria, Germany, Holland, Switzerland and Yugoslavia, halometasone cream exhibited a very satisfactory therapeutic effect in acute contact dermatitis, atopic dermatitis, nummular dermatitis and seborrhoeic dermatitis. It yielded 'good' to 'very good' results in 89.7% of the 333 patients treated with halometasone cream. Halometasone cream was significantly more effective than Diproderm, Diprosone and Ultralan creams with respect to the overall success rate, the percentage of patients with 'very good' results and early cures. It proved marginally superior to Halciderm cream in therapeutic efficacy. The onset of therapeutic effect was more rapid in patients treated with halometasone cream than in those on treatment with comparative preparations. Halometasone cream was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed. In view of the rapid onset of action, very good efficacy and tolerability, halometasone cream, with agreeable cosmetic and applicatory properties, may be considered as a suitable corticosteroid topical for the treatment of acute eczematous and other corticosteroid-responsive dermatoses. Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Double-Blind Method; Eczema; Female; Humans; Male; Middle Aged | 1983 |
An overview of international clinical trials with halometasone ointment in chronic eczematous dermatoses.
Four international, multicentre, comparative clinical trials were carried out by twenty-two dermatologists in 569 patients with non-infected chronic eczematous dermatoses in Austria, Germany, Spain, Switzerland and Yugoslavia. In these clinical trials halometasone ointment exhibited a very satisfactory therapeutic effect in all the five types of non-infected chronic eczematous dermatitis, namely chronic contact dermatitis, atopic dermatitis, lichen simplex chronicus, seborrhoeic dermatitis and nummular dermatitis. It yielded an overall success rate ('good' to 'very good' results) of 85% as against 71% obtained with the comparative preparations. With regard to therapeutic effect, halometasone ointment proved significantly superior (p = 0.0001) to Ultralan ointment but it was less effective than Dermovate ointment (p = 0.052). It yielded overall success rates higher than those obtained with Diproderm (84.6% versus 74.4%) and Synalar (88.5% versus 72%) ointments. Halometasone ointment was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed. Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Male; Middle Aged; Ointments; Random Allocation | 1983 |
Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses.
Fifty children suffering from non-infected chronic eczematous dermatoses were treated with an ointment containing 0.05% halometasone, a new high potency trihalogenated synthetic corticosteroid. Halometasone ointment does not contain parabens or perfumes. The trial population consisted of patients (under 1 to 16 years old) with non-infected chronic nummular dermatitis, seborrhoeic dermatitis, atopic dermatitis and contact dermatitis. Halometasone ointment yielded very satisfactory therapeutic results and exhibited an excellent tolerability. It produced 'good' or 'very good' results in 82% of the patients and gave an overall cure rate of 76%. The number of patients obtaining an early cure, i.e. in less than 30 days, was thirty-six (72%). An early onset of therapeutic effect, i.e. within 6 days of starting the treatment, was reported in 77.1% of the patients. All the children (including eighteen infants) tolerated halometasone ointment well and no adverse effects, either due to local skin intolerability or the transcutaneous systemic absorption of the corticoid, were observed in this trial, nor were any instances of skin atrophy reported. Cosmetic acceptability and ease of application were considered 'good' in forty-nine (98%) patients. Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Infant; Male; Ointments | 1983 |
Clinical evaluation on the long-term use of halometasone ointment in chronic eczema and psoriasis.
This clinical evaluation to determine the long-term therapeutic efficacy and tolerability of 0.05% halometasone ointment was carried out in fifty patients (forty-one with psoriasis and nine with chronic eczema) by seven dermatologists in Austria and Switzerland. The ages ranged from 19 to 76 years and the total duration of illness was more than 5 years in 62% of the trial population. The duration of treatment varied from 38 to 103 days (38-60 days in twenty-two patients, 61-90 days in twenty-five patients and 91-103 days in three patients). All patients received two non-occlusive applications of halometasone ointment per day. In this long-term study halometasone ointment exhibited very satisfactory therapeutic efficacy and very good tolerability. 'Good' to 'very good' results were reported in 73% and 89% of the patients with psoriasis and chronic eczema treated with halometasone ointment, respectively. Adverse effects were reported in only two (4%) patients who had transient itching at the site of application. Neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed in this study, nor were any instances of contact skin allergy reported. Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clinical Trials as Topic; Eczema; Female; Humans; Male; Middle Aged; Ointments; Psoriasis | 1983 |
A comparative multicentre trial of halometasone/triclosan cream and betamethasone dipropionate/gentamicin sulphate cream in the treatment of infected acute eczematous dermatitis.
A multicentre, between-patient, comparative trial was carried out to compare the efficacy and tolerability of a cream containing 0.05 halometasone and 1% triclosan with those of a cream with 0.05% betametasone dipropionate and 0.1% gentamicin sulphate in patients suffering from infected acute ezcematous dermatoses. In the evaluable trial population, consisting of 265 patients, halometasone/triclosan cream yielded a significantly (p = 0.001) higher success rate ('good' to 'very good' results), namely 96%, than the comparative cream (80%). Halometasone/triclosan cream also displayed a significantly (p = 0.008) higher cure rate (73.9%) than that observed with the comparative preparation (58.6%). The proportion of patients obtaining an early cure, i.e. in less than 20 days, was significantly (p = 0.0005) higher with halometasone/triclosan cream (42.5%) than with the comparative preparation (22.6%). The two preparations did not differ significantly with regard to the incidence and severity of adverse effects. Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Drug Combinations; Eczema; Female; Gentamicins; Humans; Male; Middle Aged; Phenyl Ethers; Triclosan | 1983 |
Evaluation of halometasone cream in the treatment of paediatric patients with acute eczematous dermatoses.
Sixty children under 10 years of age (including 18 under 3 years) suffering from non-infected acute eczematous dermatoses were treated with 0.05% halometasone cream containing a new high-potency trihalogenated synthetic dermatocorticosteroid. The trial population consisted of patients with acute atopic dermatitis, seborrhoeic dermatitis, nummular dermatitis and contact dermatitis. Halometasone cream yielded very satisfactory results and showed excellent tolerability. It produced 'good' or 'very good' results in 90% of the cases and gave an overall cure rate of 74.3%. The number of patients obtaining an early cure, i.e. in less than 20 days, was thirty-seven (62%). The onset of action was reported in 78.3% of the patients within 3 days of starting the treatment. All patients tolerated the treatment well and no adverse effects, either due to the topical application or the transcutaneous systemic absorption of the corticoid, were reported. Topics: Acute Disease; Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Clinical Trials as Topic; Eczema; Female; Humans; Infant; Male | 1983 |
[Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate].
In a multicenter controlled study carried out in Austria and Switzerland by 8 dermatologists in 208 patients with acute eczematous dermatoses, 0.05% halometasone cream proved to have significantly superior clinical efficacy than 0.05% betamethasone dipropionate cream (P much less than 0.05) showing an equal tolerability. Good to very good results were reported in 93% of the patients treated with halometasone and in 84% of those treated with betamethasone dipropionate creams (Diprosone, Diproderm). General tolerability of both treatments was good. Neither skin atrophy nor any systemic adverse effect, due to the transcutaneous absorption of the corticoids, were observed in this study. Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Drug Tolerance; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged | 1983 |
2 other study(ies) available for halometasone and Eczema
Article | Year |
---|---|
Effect of halometasone cream combined with Simiao pill on the therapeutic effect and expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP) in patients with eczema, and the factors influencing its clinical efficacy.
Chronic eczema has the characteristics of a long treatment cycle and repeated attacks, which seriously affects the daily life and work of patients. Topical glucocorticoids are the first-line treatment for chronic eczema. This study aimed to retrospectively analyze the effects of halometasone cream combined with Simiao pill on the efficacy and expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP) in patients with eczema, and identify the factors influencing its clinical efficacy.. We retrospectively collected the medical records of 195 patients with chronic eczema treated in the dermatology department from January 2020 to May 2021, and divided them into two groups according to medication: 98 cases were treated with halometasone cream (control group) and 97 cases were treated with halometasone ointment combined with Simiao pill (observation group). The severity of eczema, quality of life, clinical efficacy, LTB4 and TSLP levels, and safety were compared between the two groups. Multivariate logistic regression analysis was used to determine the independent factors affecting clinical efficacy.. After treatment, the Eczema area and severity index (EASI) and Dermatology Life Quality Index (DLQI) scores in the observation group were markedly lower than those of the control group (P<0.05). The total clinical effective rate of the observation group was 88.8%, which was notably higher than that of the control group 70.1% (P=0.001). The concentrations of serum LTB4 and TSLP in the observation group were markedly lower than those in the control group (P<0.05). Logistic regression analysis showed that the treatment regimen, digestive system symptoms, heavy aching limbs, and damp-heat tongue and pulse were independent factors affecting the curative effect of the patients (P<0.05).. Simiao pill combined with halometasone cream can effectively improve chronic eczema and enhance the clinical efficacy of treatment, which may be related to the reduction of serum LTB4 and TSLP levels. The treatment plan, digestive system symptoms, heavy aching limbs, and damp-heat tongue and pulse are the main factors that affecting the clinical curative effect. Thus, clinical intervention programs should be made according to the above factors to improve the quality of life of patients. Topics: Betamethasone; Cytokines; Eczema; Humans; Leukotriene B4; Quality of Life; Retrospective Studies; Thymic Stromal Lymphopoietin; Treatment Outcome | 2021 |
[Sicorten in the treatment of eczema, neurodermatitis and lichen ruber planus].
Topics: Adolescent; Adult; Betamethasone; Eczema; Female; Humans; Lichen Planus; Male; Middle Aged; Neurodermatitis | 1987 |